Barchas Isaac 4
4 · Immunome Inc. · Filed Jul 7, 2026
Research Summary
AI-generated summary of this filing
Immunome (IMNM) Director Isaac Barchas Sells 100,000 Shares
What Happened
Isaac Barchas, a director of Immunome Inc. (IMNM), sold a total of 100,000 shares in two open-market transactions: 83,094 shares on 2026-07-06 at a weighted-average price of $24.11 for proceeds of $2,003,396, and 16,906 shares on 2026-07-07 at a weighted-average price of $24.20 for proceeds of $409,125. Total proceeds were approximately $2,412,521. These were sales (not purchases) and therefore are typically considered routine liquidity rather than a direct bullish signal.
Key Details
- Transaction dates and amounts:
- 2026-07-06: 83,094 shares sold; weighted avg. price $24.11; proceeds $2,003,396. Price range reported: $24.00–$24.29. (Footnote: full per-price breakdown available on request.)
- 2026-07-07: 16,906 shares sold; weighted avg. price $24.20; proceeds $409,125. Price range reported: $24.00–$24.58. (Footnote: full per-price breakdown available on request.)
- Plan/authorization: Sales were made automatically under a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (referred to as ABHMC) on March 31, 2026.
- Ownership/beneficial interest: ABHMC owns the shares sold; Barchas is a managing member with power of attorney over those shares and disclaims beneficial ownership except to the extent of any pecuniary interest.
- Filing timeliness: Report filed 2026-07-07 for transactions on 2026-07-06 and 2026-07-07 — appears to be timely.
- Shares owned after transaction: Not disclosed in the provided filing.
Context
Because these sales were executed under a Rule 10b5-1 plan and by an entity (ABHMC) that holds the shares, they were likely pre-scheduled and should not be taken alone as a statement about the company’s near-term prospects. For retail investors, purchases typically carry more direct informational weight than routine sales; here the filing documents institutional/plan-driven sales rather than an immediate exercise-and-sell or gift.
Insider Transaction Report
- Sale
Common Stock
[F1][F2][F3]2026-07-06$24.11/sh−83,094$2,003,396→ 125,410 total(indirect: See footnote) - Sale
Common Stock
[F1][F4][F3]2026-07-07$24.20/sh−16,906$409,125→ 108,504 total(indirect: See footnote)
- 103,259
Common Stock
Footnotes (4)
- [F1]The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026.
- [F2]The weighted average sale price for the transaction report was $24.11, and the range of prices were between $24.00 and $24.29, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
- [F4]The weighted average sale price for the transaction report was $24.20, and the range of prices were between $24.00 and $24.58, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.